HomeENGLISH MAGAZINEBreast cancer in the outer: exosomes "cross the line" to siege brain

Breast cancer in the outer: exosomes “cross the line” to siege brain

Metastasizing breast cancers typically seek out the bones, lungs and brain. Brain metastases are especially dangerous; many women survive for less than a year after diagnosis. How is the cancer able to get past the blood-brain barrier? And can it be blocked? Those questions led PhD candidate Golnaz Morad, DDS, and her mentor Marsha Moses, PhD, who directs the Vascular Biology Program at Boston Children’s Hospital PhD, to conduct an in-depth investigation of exosomes, also known as extracellular vesicles or exosomes (EVs), and their role in breast-to-brain metastasis. Dr. Golnaz was able to identify the mechanism by which EVs pass through the blood-brain barrier and provide a ‘niche’ so that breast cancer cells can metastasize to brain. Their surprising findings appear in the journal ACS Nano. Simply put, exosome are tiny lipid bubbles released by cells, encapsulating chemical messages within. In the case of cancer cells, EVs carry factors that help create a more hospitable environment for both the primary tumor and its metastases, as Moses and Morad detailed recently in a review article. Primary tumors can secrete EVs into the circulation, allowing them to travel to distant organs and help spread the cancer.

The main question was, how can EVs reach the brain in the first place? The blood brain barrier doesn’t allow anything larger than 400 daltons to passively get into brain tissue. Exosomes are more than two thousand times larger than the size cutoff limit. The blood-brain barrier (BBB) is a complex structure made up of three kinds of cells. EVs traveling in the blood first encounter tightly joined brain endothelial cells. Pericytes comprise the next layer, followed by astrocytes (the “feet,” which connect to the cell bodies). Crosstalk between the cells circles the wagons even tighter: Astrocytes and pericytes send cues to the endothelial cells to tighten up the junctions. Morad, Moses, and colleagues worked with several models of the BBB, including in vitro microfluidic models of the BBB (“BBB on a chip”), as well as static in vitro models and live zebrafish and mouse models. The labs of Donald Ingber, MD, PhD, and Leonard Zon, MD, collaborated in the development of the BBB-on-a-chip and zebrafish models, respectively. The Moses Lab also collaborated with the lab of Christopher Carman, PhD, of Harvard’s School of Public Health for the high-resolution imaging conducted in this study.

Each model and technique provided its own insights. Bottom line, Morad and Moses showed, for the first time, that rather than squeezing in between the cells in the BBB to get into the brain, the exosomes trick the endothelial cells into taking them up. Using a standard biological pathway called transcytosis, the cells simply engulfed the EVs, bringing them inside and releasing them into brain tissue like so many Trojan horses. Exosoms can also manipulate endothelial cells to facilitate their own transport across the BBB. They hijack the pathways involved in the uptake and sorting of molecules and change regulation of the pathways. Ongoing work in the Moses Lab shows that once the EVs have breached the barrier, they trick astrocytes into sending signals to the surrounding environment, making it more receptive to tumor growth. An inventory of these signals, using mass spectrometry and other techniques, identified some that are known to degrade the network of proteins providing structural and biochemical support to brain cells. For the study, Morad had to develop special molecular biology methods to harvest enough exosomes and to verify their identity.

Having discovered what exosomes do to help breast cancer metastasize to the brain, the Moses Lab hopes to overturn things and use exosomes (or synthetic versions) to deliver anticancer drugs that home to the metastatic site.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Morad G, Carman CV et a., Moses MA. ACS Nano 2019 Sep 10. 

Gomari H et al. Onco Targets Ther. 2018 Sep 12; 11:5753-62. 

Matsumoto J et al. Curr Pharm Des. 2017; 23(40):6206-6214.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -